ABO Histo-Blood Groups Influence Makeup of Gut Microbiome
By LabMedica International staff writers Posted on 01 Feb 2021 |

Image: False-colored electron microscopic image of Bifidobacterium that are one of the major genera of bacteria that make up the gastrointestinal tract and are associated with variants in the lactase gene locus (Photo courtesy of The Keck Science Department of the Claremont Colleges)
Recent genome-wide association studies yielded inconsistent, underpowered and rarely replicated results such that the role of human host genetics as a contributing factor to microbiome assembly and structure remains uncertain.
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
Latest Molecular Diagnostics News
- New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
- Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
- AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
- DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
- Molecular Diagnostics System Provides Lab-Quality Results at POC
- Cellular Signature Identifies Patients with Treatment Resistant Prostate Tumors
- MCED Could Be Valuable Supplement to Traditional Cancer Screening Approaches
- Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
- Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
- Rapid Tests for Chagas Disease Improves Diagnostic Access
- Simple Blood Test to Predict Alzheimer’s Clinical Progression in Earliest Stages
- Saliva Test Could Identify People Genetically Susceptible to Type 2 Diabetes
- Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics
- RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
- New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
- Injury Molecular Fingerprint Enables Real-Time Diagnostics for On-Site Treatment
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more
Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
Genetic diseases are the leading identifiable cause of infant mortality, and early diagnosis is crucial to improve patient outcomes. In the neonatal and pediatric intensive care units (NICU and PICU),... Read more
AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
Cancer remains a major challenge in healthcare due to difficulties in early detection and accurate diagnosis. Many cancers are diagnosed at advanced stages, limiting treatment options and impacting survival rates.... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read morePathology
view channel
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
2025 COMPAMED Innovation Forum Highlights Pioneering Work in Cancer Diagnostics
Cancer cases are among the biggest challenges faced by global healthcare systems. The incidence has risen in recent decades, not least on account of demographic change and escalating risk factors.... Read more
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more